Evotec’s Post

#ADCs are in the limelight at the Evotec and Cyprotex-hosted session at the #EUROTOX Congress. Join Dario Salerno, and Giulia Iannoto, on Monday, 9 September 2024, 12:00-13:00 to learn how to navigate preclinical development for ADCs. #toxicology #safetyassessment #oncology #personalizedmedicine #drugdevelopment #researchneverstops #biopharmaceuticals #immunology #rnaseq #cardiotoxicity #antibody

Join Us at Eurotox 2024! We are thrilled to invite you to two exciting events hosted by Evotec and Cyprotex at Eurotox 2024! Don't miss these opportunities to gain valuable insights and network with industry experts. Industry Hosted Session Topic: Navigating the Preclinical Development of Antibody Drug Conjugates (ADCs) Focus: Toxicology De-Risking Strategies for Enabling Personalized Medicine Date & Time: Monday, 9 September 2024, 12:00-13:00 Presenters: Dario Salerno, Senior Manager, Safety Assessment, and Giulia Iannoto, Immunotoxicologist, Safety Assessment Session Highlights: - Explore the complexities of ADCs, biopharmaceutical molecules designed to target cancer cells. - Understand the unique challenges in nonclinical safety assessment of ADCs. - Learn about the science-based approach to safety assessment and current regulatory guidelines. - Discover our recent case study and experiences with ADCs. Poster Presentation Title: Multiparametric In Vitro Assays Combined with High-Throughput RNA Sequencing for Cardiotoxicity Risk Assessment and Mechanistic Insight (#916) Date and time: Monday, 9 September 2024, 9:30am Presenter: Samantha Llewellyn, Associate Principal Scientist - Cyprotex Join us to delve into innovative methodologies for cardiotoxicity risk assessment and gain mechanistic insights through high-throughput RNA sequencing. Don't miss these sessions to stay at the forefront of toxicology and preclinical development. We look forward to seeing you there! #Eurotox2024 #ADCs #Toxicology #PreclinicalDevelopment #Cardiotoxicity #PersonalizedMedicine https://hubs.ly/Q02L3V0D0

Join Us at Eurotox 2024! We are thrilled to invite you to two exciting events hosted by Evotec and Cyprotex at Eurotox 2024! Don't miss these opportunities to gain valuable insights and network with industry experts. Industry Hosted Session Topic: Navigating the Preclinical Development of Antibody Drug Conjugates (ADCs) Focus: Toxicology De-Risking Strategies for Enabling Personalized Medicine Date & Time: Monday, 9 September 2024, 12:00-13:00 Presenters: Dario Salerno, Senior Manager, Safety Assessment, and Giulia Iannoto, Immunotoxicologist, Safety Assessment Session Highlights: - Explore the complexities of ADCs, biopharmaceutical molecules designed to target cancer cells. - Understand the unique challenges in nonclinical safety assessment of ADCs. - Learn about the science-based approach to safety assessment and current regulatory guidelines. - Discover our recent case study and experiences with ADCs. Poster Presentation Title: Multiparametric In Vitro Assays Combined with High-Throughput RNA Sequencing for Cardiotoxicity Risk Assessment and Mechanistic Insight (#916) Date and time: Monday, 9 September 2024, 9:30am Presenter: Samantha Llewellyn, Associate Principal Scientist - Cyprotex Join us to delve into innovative methodologies for cardiotoxicity risk assessment and gain mechanistic insights through high-throughput RNA sequencing. Don't miss these sessions to stay at the forefront of toxicology and preclinical development. We look forward to seeing you there! #Eurotox2024 #ADCs #Toxicology #PreclinicalDevelopment #Cardiotoxicity #PersonalizedMedicine https://hubs.ly/Q02L3V0F0

So excited that we are hosting the #BAPTG spring meeting tomorrow! Looking forward to learning more about novel tools to accelerate drug discovery & development and regulatory guidance on safety assessment for cell therapy, ADCs & TCEs in oncology, autoimmunity, and other therapeutic areas. #celltherapy #toxicology #oncology #autoimmunity #immunology #AstraZeneca

Everything you missed in #Pharma & #Biotech 🦠🔬   ✅ Approvals Boston Scientific receives FDA approval for the AGENT Drug-Coated Balloon for coronary in-stent restenosis in coronary artery disease CHMP recommends Biogen’s Qalsody® (tofersen) for rare form of ALS (SOD1 gene mutation)   💸 Deals   AstraZeneca to acquire Gracell Biotechnologies for $1.2 Billion Amneal Pharmaceuticals, Inc. enters EU/UK/CH licensing agreement with Zambon Biotech for IPX203, oral carbidopa/levodopa extended-release capsules for Parkinson’s, currently under review with the FDA Idorsia Pharmaceuticals Ltd entered R&D agreement including two Ph3 assets (CV and autoimmune) with Viatris Abingworth offers Gilead Sciences up to $210 million to support select clinical studies of antibody-drug conjugate Trodelvy, with a focus on non-small cell lung cancer BlossomHill Therapeutics, Inc. raises $100 million in series B for oncology and autoimmune development Telix Pharmaceuticals Limited to aquire IsoTherapeutics Group LLC, a specialty radiopharmaceutical development and bioconjugation firm   Suven Pharmaceuticals and Cohance Lifesciences announce merger   Takeda partners with Biological E. Limited to boost dengue vaccine Qdenga® production     🎯Late-stage developments   MoonLake Immunotherapeutics (NASDAQ: MLTX) to advance IL-17 inhibitor into Ph3 following positive feedback from FDA and EMA   👀 To watch   Pfizer shares roadmap for cancer portfolio with vision to launch at least eight cancer blockbuster drugs by 2030 following Seagen acquisition, with focus on genitourinary (eg prostate and bladder), blood (eg multiple myeloma and lymphomas), breast, lung and head and neck   📈 Access   Delaware judge dismisses AstraZeneca's challenge to IRA drug price provisions. AZ’s diabetes, kidney and heart drug Farxiga is one of ten products facing Medicare price negotiations   ✳️ Other:   Biden administration invests $48M in AI/ML platform to identify rare disease drugs   👉 What’s your favorite industry news?   #pharma #biotech #PulseNews

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics. To find out more take a look at this frontrunners in bispecific antibodies article: https://lnkd.in/ehE36z29

Do you want to become incredibly well read on the latest drug therapies – in just a few minutes? 👇Then check out our brand new #DrugDevelopment blog – outlining the state-of-the art treatments that were approved by the FDA in 2023, a memorable year for novel therapies. https://okt.to/iI7r2U 💡 The blog also previews some of the key drugs that are expected to be approved in 2024 – including an Alzheimer’s targeting monoclonal antibody and an MDMA treatment for PTSD. ✅ Getting up to speed on the latest therapeutic developments – from AKT inhibitors to Alzheimer’s disease, and oncology to orphan drugs – has never been so easy! ****** ***** ***** Did you know? LGC Standards’ Toronto Research Chemicals range supplies bioactive molecules for research into cancer, infectious diseases, neuroscience and more, while LGC Mikromol™ offers 5,000 pharmaceutical reference standards. ***** ***** ***** #ScienceForASaferWorld

Do you want to become incredibly well read on the latest drug therapies – in just a few minutes? 👇Then check out our brand new #DrugDevelopment blog – outlining the state-of-the art treatments that were approved by the FDA in 2023, a memorable year for novel therapies. https://okt.to/U4tMz8 💡 The blog also previews some of the key drugs that are expected to be approved in 2024 – including an Alzheimer’s targeting monoclonal antibody and an MDMA treatment for PTSD. ✅ Getting up to speed on the latest therapeutic developments – from AKT inhibitors to Alzheimer’s disease, and oncology to orphan drugs – has never been so easy! ****** ***** ***** Did you know? LGC Standards’ Toronto Research Chemicals range supplies bioactive molecules for research into cancer, infectious diseases, neuroscience and more, while LGC Mikromol™ offers 5,000 pharmaceutical reference standards. ***** ***** ***** #ScienceForASaferWorld

Merck will pay Curon Biopharmaceutical, a China-based biotech company, $700M upfront for rights to a bispecific antibody treatment code-named CN201. Several approved #celltherapies and bispecific drugs have already proven able to treat select blood #cancers. Research has suggested the same strategy can be used to treat #autoimmunediseases and CN201 has the potential to become a “novel, scalable option” for #autoimmune. Roche has two drugs in early testing, Zenas Biopharma will soon begin Phase 2 trials in #lupus and #multiplesclerosis while Cullinan Therapeutics is on the verge of trials in lupus and #rheumatoidarthritis.

GSK and Chimagen Biosciences (Chimagen), a privately held biotechnology company, today announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from Chimagen for $300 million upfront. GSK plans to develop and commercialize CMG1A46 with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases. #antibody #antibodies #mAb #mAbs #Biologics #Tcellengager #TCE #TCEs #SLE #LN #autoimmunediesease https://lnkd.in/e9nyVUjp